［1］ Brewer GJ, Yuzbasiyan-Gurkan V. Wilson disease［J］. Medicine (Baltimore), 1992, 71(3):139-164.
［2］Brewer GJ, Fink JK, Hedera P. Diagnosis and treatment of Wilson disease［J］. Semin Neurol, 1999, 19(3):261-270.
［3］Brewer GJ, Askari FK. Wilson disease: clinical management and therapy［J］. J Hepatol, 2005, 42(Suppl 1):s13-21.
［4］Merle U, Schaefer M, Ferenci P, Stremmel W. Clinical presentation, diagnosis and long-term outcome of Wilson's disease:a cohort study［J］. Gut, 2007, 56(1):115-120.
［5］杨任民. 肝豆状核变性［M］. 合肥: 安徽科技出版社，1995：167-168.
［6］Young AB, Shoulson I, Penney JB, StarostaRubinstein S, Gomez F, Travers H, et al. Huntington's disease in Venezuela: neurologic features and functional declinc［J］. Neurology, 1986, 36(3):244.
［7］Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, Tankanow R, Young AB, Kluin KJ. Initial therapy of patients with Wilson's disease with tetrathiomolybdate［J］. Arch Neurol, 1991, 48(1):42-47.
［8］Yuzbasiyan-Gurkan V, Grider A, Nostrant T, Cousins RJ, Brewer GJ. Treatment of Wilson's disease with zinc: X. Intestinal metallothionein induction［J］. J Lab Clin Med, 1992, 120(3):380-386.
［9］Hoogenraad TU. Paradigm shift in treatment of Wilson's disease: zinc therapy now treatment of choice［J］. Brain Dev, 2006, 28(3):141-146.
［10］Brewer GJ, Askari F, Lorincz MT, Carlson M, Schilsky M, Kluin KJ, et al. Treatment of Wilson Disease with ammonium tetrathiomolybdate IV. Comparison of tetrathiomolybdate and trientine in a double-blind study of treatment of the neurologic presentation of Wilson disease［J］. Arch Neurol, 2006, 63(4):521-527.
［12］Mcquaid A, Lamand M, Mason J. The interactions of penicillamine with copper in vivo and the effect on hepatic metallothionein levels and copper/zinc distribution［J］. Lab Clin Med, 1992, 119(6):744.
［13］Brewer GJ, Hedera P, Kluin KJ, Carlson M, Askari F, Dick RB, et al. Treatment of Wilson Disease with ammonium tetrathiomolybdate III. Initial therapy in a total of 55 neurologically affected patients and follow-up with zinc therapy［J］. Arch Neurol, 2003, 60(3):379-385.
